Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study

被引：0
作者：
Xinguang Wang
Zhaoqing Fan
Xing Wang
Yingjian He
Yiqiang Liu
Xiang Wang
Bailin Zhang
Zefei Jiang
Tao Wang
Zhigang Yu
Fei Wang
Yinhua Liu
Yanping Li
Jianguo Zhang
Bin Luo
Hongchuan Jiang
Tianfeng Wang
Yuntao Xie
Jinfeng Li
Tao Ouyang
机构：
[1] Peking University Cancer Hospital & Institute,Breast Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Peking University Cancer Hospital & Institute,Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Breast Surgical Oncology
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Oncology
[5] The Fifth Medical Center of PLA General Hospital,Department of Breast Surgery, Cheeloo College of Medicine, The Second Hospital
[6] Shandong University,Breast Disease Center
[7] Peking University First Hospital,Department of Breast Surgery, Beijing Shijitan Hospital
[8] Capital Medical University,Department of Breast Surgery
[9] The Second Hospital of Harbin Medical University,Department of General Surgery, Clinical School of Medicine, Tsinghua Changgung Hospital
[10] Tsinghua University,Department of Breast Surgery, Beijing Chao Yang Hospital
[11] Capital Medical University,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 195卷
关键词：
Neoadjuvant endocrine therapy; Breast cancer; Pathological response; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 310
页数：9
相关论文
共 464 条
  • [11] Quackenbush JF(2008)Response to neoadjuvant therapy and long term survival in patients with triple negative breast cancer J Clin Oncol 26 1275-1281
  • [12] Stijleman IJ(2008)Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 1380-1388
  • [13] Palazzo J(2017)Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer Breast 34 S104-S107
  • [14] Marron JS(2019)Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States Breast Cancer Res Treat 178 419-426
  • [15] Nobel AB(2011)Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group J Natl Cancer Inst 103 1656-1664
  • [16] Mardis E(2021)Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group J Natl Cancer Inst 113 808-819
  • [17] Nielsen TO(1981)Reporting results of cancer treatment Cancer 47 207-214
  • [18] Ellis MJ(2003)A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 320-327
  • [19] Perou CM(2013)Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer Chin J Cancer Res 25 397-404
  • [20] Bernard PS(2019)Trastuzumab emtansine for residual invasive HER2-positive breast cancer N Engl J Med 380 617-628
12345678910